Martina Carullo

AIOM Giovani ~ @AIOMtweet Florence, 11-12 July ♥️

💥 Phase II ShorTrip study #ESMOGI25: SCRT → 1 cycle FOLFOX + 7 cycles FOLFOXIRI as TNT in #LARC 🎯 pCR in 33% | MPR in 69% 🎯 77% completed all 8 cycles ⚠️ Toxicities manageable after early amendment Short-course RT, long-term potential — the ShorTrip may lead to a major…

So proud of you @p_ciracimd 🤍

How do depth of response and early tumor shrinkage impact outcomes in BRAFV600E-mutated metastatic colorectal cancer? A new study explores how DpR predicts progression-free survival in patients treated with encorafenib + cetuximab ± binimetinib Read here: journals.sagepub.com/doi/epdf/10.11…

Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients 👉 rdcu.be/d0AHE @ChiaraCrem1 @VStudiale @carlottanto1 @NatRevClinOncol

Had the chance to give my first speech at #AIOM24 National Congress, presenting the phase 1 TriComB study results on behalf of the @FoundationGono investigators. Big thanks to @AIOMtweet for this opportunity!

#ESMOGI24 has been incredible! @myESMO

#ESMOGI24 is coming to an end… an excellent first time! Science, networking and fun… highly recommendable! Now ready to bring energy and motivation to our daily life and patients. ⁦@VStudiale⁩ ⁦⁦@p_ciracimd⁩ ⁦@myESMO⁩ #ESMOAmbassadors

Another great session on colorectal cancer with an amazing presentation of @ChiaraCrem1 📌 How to choice first line treatment in pMMR mCRC 👭🏻 With a contribution of my friend @martweetings @myESMO #ESMOGI24

All disease begins in the gut! Great speech by Laurence Zitvogel at @myESMO ✨

Exciting Poster session at ⁦@myESMO⁩ 💫 Liver metastases in mCRC and immuno-therapy: love is still in the air? At Poster Session today, a secondary analysis of the AtezoTRIBE trial. ⁦@ChiaraCrem1⁩ ⁦@carlottanto1⁩ ⁦@FoundationGono⁩

p16 as a potential marker of benefit from irinotecan in mCRC…congrats ⁦@VStudiale⁩ for your work being selected as best poster in colon cancer at #ESMOGI24 ⁦@Unipisa⁩ ⁦@FoundationGono⁩ @myesmo #EsmoAmbassadors

Great presentations during the Proffered Paper Session at ESMO GI 2024 ✨ 💫 Safety results of TRANSMET 💫 HRQoL data of CheckMate8HW 💫 Trifluridine-Tipiracil and Regorafenib endless battle: new warriors unlocked And outstanding discussion by @ChiaraCrem1 ❤️ @myESMO

Got the chance to briefly meet Dr. @MyriamChalabi after her remarkable presentation on IO for pMMR #CRC. 👏 Definitely one of the most intriguing research topics in the field! @myESMO #ESMOGI24

pMMR Colorectal cancer Stunning Keynote Lecture by @MyriamChalabi ✨✨✨

European Championship of gastrointestinal oncology? ⚽ Brilliant keynote lecture on KRAS inhibitors by Dr. Corcoran at #ESMOGI24

Pisa team ready to take off ✈️ to the first #ESMOGI meeting. Cannot wait to meet friends and discuss news in GI oncology. ⁦@myESMO⁩ ⁦⁦

#ESMOGI24: Do not miss the latest GI #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation. 👉 ow.ly/ag6K50So0Qt

Best colleagues and friends ever! Ready for Atezo2!

Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn nej.md/3Ku4X0H